StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays lowered their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Price Performance

NASDAQ:CLLS opened at $2.10 on Friday. Cellectis has a 52-week low of $1.70 and a 52-week high of $3.77. The stock has a fifty day moving average of $1.95 and a 200 day moving average of $2.17. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The firm has a market capitalization of $116.72 million, a price-to-earnings ratio of -1.62 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the company posted ($0.31) earnings per share. On average, research analysts expect that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new position in Cellectis during the 2nd quarter valued at about $29,000. First Affirmative Financial Network purchased a new position in shares of Cellectis during the third quarter valued at approximately $45,000. Principal Financial Group Inc. raised its holdings in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC lifted its stake in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.